Atea Pharmaceuticals AVIR Stock
Atea Pharmaceuticals Price Chart
Atea Pharmaceuticals AVIR Financial and Trading Overview
| Atea Pharmaceuticals stock price | 2.89 USD |
| Previous Close | 4.09 USD |
| Open | 4.08 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 1000 |
| Day's Range | 4.01 - 4.2 USD |
| 52 Week Range | 2.94 - 9.79 USD |
| Volume | 413.55K USD |
| Avg. Volume | 783.6K USD |
| Market Cap | 346.11M USD |
| Beta (5Y Monthly) | 0.223085 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4 USD |
AVIR Valuation Measures
| Enterprise Value | -271435584 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.4612677 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.55990285 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 2.093 |
Trading Information
Atea Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.223085 |
| 52-Week Change | -36.15% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.79 USD |
| 52 Week Low | 2.94 USD |
| 50-Day Moving Average | 3.73 USD |
| 200-Day Moving Average | 4.59 USD |
AVIR Share Statistics
| Avg. Volume (3 month) | 783.6K USD |
| Avg. Daily Volume (10-Days) | 536.85K USD |
| Shares Outstanding | 83.4M |
| Float | 69.67M |
| Short Ratio | 1.58 |
| % Held by Insiders | 9.10% |
| % Held by Institutions | 70.67% |
| Shares Short | 1.87M |
| Short % of Float | 2.91% |
| Short % of Shares Outstanding | 2.23% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -11.99% |
| Return on Equity (ttm) | -16.83% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -81936000 USD |
| EBITDA | -129687000 USD |
| Net Income Avi to Common (ttm) | -109299000 USD |
| Diluted EPS (ttm) | -1.31 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 620.49M USD |
| Total Cash Per Share (mrq) | 7.44 USD |
| Total Debt (mrq) | 2.95M USD |
| Total Debt/Equity (mrq) | 0.48 USD |
| Current Ratio (mrq) | 51.16 |
| Book Value Per Share (mrq) | 7.412 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -91823000 USD |
| Levered Free Cash Flow (ttm) | -56308500 USD |
Profile of Atea Pharmaceuticals
| Country | United States |
| State | MA |
| City | Boston |
| Address | 225 Franklin Street |
| ZIP | 02110 |
| Phone | 857 284 8891 |
| Website | https://ateapharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 73 |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Q&A For Atea Pharmaceuticals Stock
What is a current AVIR stock price?
Atea Pharmaceuticals AVIR stock price today per share is 2.89 USD.
How to purchase Atea Pharmaceuticals stock?
You can buy AVIR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Atea Pharmaceuticals?
The stock symbol or ticker of Atea Pharmaceuticals is AVIR.
Which industry does the Atea Pharmaceuticals company belong to?
The Atea Pharmaceuticals industry is Biotechnology.
How many shares does Atea Pharmaceuticals have in circulation?
The max supply of Atea Pharmaceuticals shares is 85.53M.
What is Atea Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Atea Pharmaceuticals PE Ratio is now.
What was Atea Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Atea Pharmaceuticals EPS is -2 USD over the trailing 12 months.
Which sector does the Atea Pharmaceuticals company belong to?
The Atea Pharmaceuticals sector is Healthcare.
Atea Pharmaceuticals AVIR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Select Market Com NQGS | 8504.39 USD — |
+1.34
|
— — | 8367.19 USD — | 8515.13 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}